Engineering enhancement of the immune response to HBV DNA vaccine in mice by the use of LIGHT gene adjuvant

Journal of Virological Methods

Volumn 153, Issue 2, 2008, Pages 142-148

  Zhang, Yali ^a   Jiang, Wenzheng ^a   Fan, Yan ^a   Wen, Jiejun ^a   Hao, Wenli ^a   Qian, Min ^a  

^a EAST CHINA NORMAL UNIVERSITY   (China)

Author keywords

Adjuvant; DNA vaccine; HBV; Immune response; LIGHT

Indexed keywords

DNA VACCINE; HEPATITIS B SURFACE ANTIGEN; PROTEIN LIGHT; TUMOR NECROSIS FACTOR; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL PROLIFERATION; CELLULAR IMMUNITY; CONTROLLED STUDY; HEPATITIS B VIRUS; HUMORAL IMMUNITY; IMMUNE RESPONSE; IN VITRO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; FEMALE; GENETIC VECTORS; HELA CELLS; HEPATITIS B; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; HUMANS; IMMUNIZATION; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED BALB C; PLASMIDS; SPLEEN; T-LYMPHOCYTES, CYTOTOXIC; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 14; VACCINES, DNA;

ANIMALIA; EUKARYOTA; HEPATITIS B VIRUS; MURINAE; MUS;

EID: 53049090809     PISSN: 01660934     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jviromet.2008.07.013     Document Type: Article

References (52)

1. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 (1998) 245-252
2. Bocher W.O., Dekel B., Schwerin W., Geissler M., Hoffmann S., Rohwer A., Arditti F., Cooper A., Bernhard H., Berrebi A., Rose-John S., Shaul Y., Galle P.R., Lohr H.F., and Reisner Y. Induction of strong hepatitis B virus (HBV) specific T helper cell and cytotoxic T lymphocyte responses by therapeutic vaccination in the trimera mouse model of chronic HBV infection. Eur. J. Immunol. 31 (2001) 2071-2079
3. Browning J.L., Sizing I.D., Lawton P., Bourdon P.R., Rennert P.D., Majeau G.R., Ambrose C.M., Hession C., Miatkowski K., Griffiths D.A., Ngamek A., Meier W., Benjamin C.D., and Hochman P.S. Characterization of lymphotoxin-alpha beta complexes on the surface of mouse lymphocytes. J. Immunol. 159 (1997) 3288-3298
4. Chaplin P.J., DeRose R., Boyle J.S., McWaters P., Kelly J., Tennent J.M., Lew A.M., and Scheerlinck J.P. Targeting improves the efficacy of a DNA vaccine against Corynebacterium pseudotuberculosis in sheep. Infect. Immun. 67 (1999) 6434-6438
5. Chen L., Shao H.J., and Su Y.B. Coimmunization of Agaricus blazei Murill extract with hepatitis B virus core protein through DNA vaccine enhances cellular and humoral immune responses. Int. Immunopharmacol. 4 (2004) 403-409
6. Chen J.Y., and Li F. Development of hepatitis C virus vaccine using hepatitis B core antigen as immuno-carrier. World J. Gastroenterol. 12 (2006) 7774-7778
7. Chisari F.V., and Ferrari C. Hepatitis B virus immunopathogenesis. Annu. Rev. Immunol. 13 (1995) 29-60
8. Chow Y.H., Huang W.L., Chi W.K., Chu Y.D., and Tao M.H. Improvement of hepatitis B virus DNA vaccines by plasmids coexpressing hepatitis B surface antigen and interleukin-2. J. Virol. 71 (1997) 169-178
9. Couillin I., Pol S., Mancini M., Driss F., Brechot C., Tiollais P., and Michel M.L. Specific vaccine therapy in chronic hepatitis B: induction of T cell proliferative responses specific for envelope antigens. J. Infect. Dis. 180 (1999) 15-26
10. Daryani N.E., Nassiri-Toosi M., Rashidi A., and Khodarahmi I. Immunogenicity of recombinant hepatitis B virus vaccine in patients with and without chronic hepatitis C virus infection: a case-control study. World J. Gastroenterol. 13 (2007) 294-298
11. Davis H.L., Weeratna R., Waldschmidt T.J., Tygrett L., Schorr J., and Krieg A.M. CpG DNA is a potent enhancer of specific immunity in mice immunized with recombinant hepatitis B surface antigen. J. Immunol. 160 (1998) 870-876
12. Du D.W., Jia Z.S., Li G.Y., and Zhou Y.Y. HBV DNA vaccine with adjuvant cytokines induced specific immune responses against HBV infection. World J. Gastroenterol. 9 (2003) 108-111
13. Dunham S.P., Flynn J.N., Rigby M.A., Macdonald J., Bruce J., Cannon C., Golder M.C., Hanlon L., Harbour D.A., Mackay N.A., Spibey N., Jarrett O., and Neil J.C. Protection against feline immunodeficiency virus using replication defective proviral DNA vaccines with feline interleukin-12 and -18. Vaccine 20 (2002) 1483-1496
14. Garren H., Ruiz P.J., Watkins T.A., Fontoura P., Nguyen L.T., Estline E.R., Hirschberg D.L., and Steinman L. Combination of gene delivery and DNA vaccination to protect from and reverse Th1 autoimmune disease via deviation to the Th2 pathway. Immunity 15 (2001) 15-22
15. Gavarasana S., Kalasapudi R.S., Rao T.D., and Thirumala S. Prevention of carcinoma of cervix with human papillomavirus vaccine. Indian J. Cancer 37 (2000) 57-66
16. Gu Q.L., Huang X., Ren W.H., Shen L., Liu B.Y., and Chen S.Y. Targeting hepatitis B virus antigens to dendritic cells by heat shock protein to improve DNA vaccine potency. World J. Gastroenterol. 13 (2007) 5911-5917
17. Guidotti L.G., Ando K., Hobbs M.V., Ishikawa T., Runkel L., Schreiber R.D., and Chisari F.V. Cytotoxic T lymphocytes inhibit hepatitis B virus gene expression by a noncytolytic mechanism in transgenic mice. Proc. Natl. Acad. Sci. U.S.A. 91 (1994) 3764-3768
18. Harrop J.A., McDonnell P.C., Brigham-Burke M., Lyn S.D., Minton J., Tan K.B., Dede K., Spampanato J., Silverman C., Hensley P., DiPrinzio R., Emery J.G., Deen K., Eichman C., Chabot-Fletcheri M., Truneh A., and Young P.R. Herpesvirus entry mediator ligand (HVEM-L), a novel ligand for HVEM/TR2, stimulates proliferation of T cells and inhibits HT29 cell growth. J. Biol. Chem. 273 (1998) 27548-27556
19. Harrop J.A., Reddy M., Dede K., Brigham-Burke M., Lyn S., Tan K.B., Silverman C., Eichman C., DiPrinzio R., Spampanato J., Porter T., Holmes S., Young P.R., and Truneh A. Antibodies to TR2 (herpesvirus entry mediator), a new member of the TNF receptor superfamily, block T cell proliferation, expression of activation markers, and production of cytokines. J. Immunol. 161 (1998) 1786-1794
20. He X.W., Sun S.H., Hu Z.L., Li J., Jiang L., Zhou F.J., Zhang Y.N., and Guo Y.J. Augmented humoral and cellular immune responses of a hepatitis B DNA vaccine encoding HBsAg by protein boosting. Vaccine 23 (2005) 1649-1656
21. Huang Z.H., Zhuang H., Lu S., Guo R.H., Xu G.M., Cai J., and Zhu W.F. Humoral and cellular immunogenecity of DNA vaccine based on hepatitis B core gene in rhesus monkeys. World J. Gastroenterol. 7 (2001) 102-106
22. Jung M.C., Gruner N., Zachoval R., Schraut W., Gerlach T., Diepolder H., Schirren C.A., Page M., Bailey J., Birtles E., Whitehead E., Trojan J., Zeuzem S., and Pape G.R. Immunological monitoring during therapeutic vaccination as a prerequisite for the design of new effective therapies: induction of a vaccine-specific CD4+ T-cell proliferative response in chronic hepatitis B carriers. Vaccine 20 (2002) 3598-3612
23. Kim J.J., Yang J.S., Manson K.H., and Weiner D.B. Modulation of antigen-specific cellular immune responses to DNA vaccination in rhesus macaques through the use of IL-2, IFN-γ, or IL-4 gene adjuvants. Vaccine 19 (2001) 2496-2505
24. Kwon B.S., Tan K.B., Ni J., Oh K.O., Lee Z.H., Kim K.K., Kim Y.J., Wang S., Gentz R., Yu G.L., Harropi J., Lyni S.D., Silvermani C., Porteri T.G., Trunehi A., and Youngi P.R. A newly identified member of the tumor necrosis factor receptor superfamily with a wide tissue distribution and involvement in lymphocyte activation. J. Biol. Chem. 272 (1997) 14272-14276
25. Kwon T.K., and Park J.W. Intramuscular co-injection of naked DNA encoding HBV core antigen and Flt3 ligand suppresses anti-HBc antibody response. Immunol. Lett. 81 (2002) 229-234
26. Lee Y.S., Yoon S.J., Kwon T.K., Kim Y.H., Woo J.H., Suh M.H., Suh S.I., Baek W.K., Kim H.J., Ahn S.Y., Choe B.K., and Park J.W. Immune response induced by immunization with Hepatitis B virus core DNA isolated from chronic active hepatitis patients. Immunol. Lett. 78 (2001) 13-20
27. Lenschow D.J., Walunas T.L., and Bluestone J.A. CD28/B7 system of T cell costimulation. Annu. Rev. Immunol. 14 (1996) 233-258
28. Loirat D., Lemonnier F.A., and Michel M.L. Multiepitopic HLA-A*0201-restricted immune response against hepatitis B surface antigen after DNA-based immunization. J. Immunol. 165 (2000) 4748-4755
29. Mancini M., Hadchouel M., Davis H.L., Whalen R.G., Tiollais P., and Michel M.L. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc. Natl. Acad. Sci. U.S.A. 93 (1996) 12496-12501
30. Mauri D.N., Ebner R., Montgomery R.I., Kochel K.D., Cheung T.C., Yu G.L., Ruben S., Murphy M., Eisenberg R.J., Cohen G.H., Spear P.G., and Ware C.F. LIGHT, a new member of the TNF superfamily, and lymphotoxic α are ligands for herpesvirus entry mediator. Immunity 8 (1998) 21-30
31. McDonnell W.M., and Askari F.K. DNA vaccines. N. Engl. J. Med. 334 (1996) 42-45
32. Michel M.L., and Loirat D. DNA vaccines for prophylactic or therapeutic immunization against hepatitis B. Intervirology 44 (2001) 78-87
33. Morel Y., Schiano de Colella J.M., Harrop J., Deen K.C., Holmes S.D., Wattam T.A., Khandekar S.S., Truneh A., Sweet R.W., Gastaut J.A., Olive D., and Costello R.T. Reciprocal expression of the TNF family receptor herpes virus entry mediator and its ligand LIGHT on activated T cells: LIGHT down-regulates its own receptor. J. Immunol. 165 (2000) 4397-4404
34. Mueller D.L., Jenkins M.K., and Schwartz R.H. Clonal expansion versus functional clonal inactivation: a costimulatory signalling pathway determines the outcome of T cell antigen receptor occupancy. Annu. Rev. Immunol. 7 (1989) 445-480
35. Murphy M., Walter B.N., Pike-Nobile L., Fanger N.A., Guyre P.M., Browning J.L., Ware C.F., and Epstein L.B. Expression of the lymphotoxin receptor on follicular stromal cells in human lymphoid tissues. Cell Death Differ. 5 (1998) 497-505
36. Musacchio A., Rodriguez E.G., Herrera A.M., Quintana D., and Muzio V. Multivalent DNA-based immunization against hepatitis B virus with plasmids encoding surface and core antigens. Biochem. Biophys. Res. Commun. 282 (2001) 442-446
37. Nobiron I., Thompson I., Brownlie J., and Collins M.E. Cytokine adjuvancy of BVDV DNA vaccine enhances both humoral and cellular immune responses in mice. Vaccine 19 (2001) 4226-4235
38. Roh S., Lee Y.K., Ahn B.Y., Kim K., and Moon A. Induction of CTL responses and identification of a novel epitope of hepatitis B virus surface antigens in C57BL/6 mice immunized with recombinant vaccinia viruses. Virus Res. 73 (2001) 17-26
39. Roy M.J., Wu M.S., Barr L.J., Fuller J.T., Tussey L.G., Speller S., Culp J., Burkholder J.K., Swain W.F., Dixon R.M., Widera G., Vessey R., King A., Ogg G., Gallimore A., Haynes J.R., and Heydenburg Fuller D. Induction of antigen-specific CD8+ T cells, T helper cells, and protective levels of antibody in humans by particle-mediated administration of a hepatitis B virus DNA vaccine. Vaccine 19 (2000) 764-778
40. Scheu S., Alferink J., Potzel T., Barchet W., Kalinke U., and Pfeffer K. Targeted disruption of LIGHT causes defects in costimulatory T cell activation and reveals cooperation with lymphotoxin beta in mesenteric lymphnode genesis. J. Exp. Med. 195 (2002) 1613-1624
41. Smith C.A., Farrah T., and Goodwin R.G. The TNF receptor superfamily of cellular and viral proteins: activation, costimulation, and death. Cell 76 (1994) 959-962
42. Tamada K., Shimozaki K., Chapoval A.I., Zhai Y.F., Su J., Chen S.F., Hsieh S.L., Nagata S., Ni J., and Chen L.P. LIGHT, a TNF-like molecule, costimulates T cell proliferation and is required for dendritic cell-mediated allogeneic T cell response. J. Immunol. 164 (2000) 4105-4110
43. Tamada K., Shimozaki K., Chapoval A.I., Zhu G., Sica G., Flies D., Boone T., Hsu H.L., Fu Y.X., Nagata S., Ni J., and Chen L.P. Modulation of T-cell-mediated immunity in tumor and graft-versus-host disease models through the LIGHT co-stimulatory pathway. Nat. Med. 6 (2000) 283-289
44. Thirdborough S.M., Radcliffe J.N., Friedmann P.S., and Stevenson F.K. Vaccination with DNA encoding a single-chain tcr fusion protein induces anticlonotypic immunity and protects against T-cell lymphoma. Cancer Res. 62 (2002) 1757-1760
45. Ulmer J.B., Donnelly J.J., and Liu M.A. Toward the development of DNA vaccines. Curr. Opin. Biotechnol. 7 (1996) 653-658
46. Watts T.H., and DeBenedette M.A. T cell co-stimulatory molecules other than CD28. Curr. Opin. Immunol. 11 (1999) 286-293
47. Wu L., Yuan Z.H., Liu F., Waters J.A., and Wen Y.M. Comparing the immunogenicity of hepatitis B virus S gene variants by DNA immunization. Viral Immunol. 14 (2001) 359-367
48. Xing Y.P., Huang Z.H., Wang S.X., Cai J., Li J., Chou T.H., and Lu S. Novel DNA vaccine based on hepatitis B virus core gene induces specific immune responses in BALB/c mice. World J. Gastroenterol. 11 (2005) 4583-4586
49. Xu W., Chu Y.W., Zhang R.H., Xu H.B., Wang Y., and Xiong S.D. Endoplasmic reticulum targeting sequence enhances HBV-specific cytotoxic T lymphocytes induced by a CTL epitope-based DNA vaccine. Virology 334 (2005) 255-263
50. Yuen M.F., and Lai C.L. Treatment of chronic hepatitis B. Lancet Infect. Dis. 1 (2001) 232-241
51. Zhang W., Dong S.F., Sun S.H., Wang Y., Li G.D., and Qu D. Coimmunization with IL-15 plasmid enhances the longevity of CD8 T cells induced by DNA encoding hepatitis B virus core antigen. World J. Gastroenterol. 12 (2006) 4727-4735
52. Zhao L.S., Qin S., Zhou T.Y., Tang H., Liu L., and Lei B.J. DNA-based vaccination induces humoral and cellular immune responses against hepatitis B virus surface antigen in mice without activation of Cmyc. World J. Gastroenterol. 6 (2000) 239-243